SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg11/29/2005 4:43:06 PM
   of 1826
 
MGI Pharma Seen Meeting 2005 Guidance For Aloxi
Peter Kang, 11.29.05, 4:07 PM ET

Prudential Equity Group said MGI Pharma (nasdaq: MOGN - news - people ) will likely meet 2005 sales goals for Aloxi despite weak monthly sales released today for the cancer pain drug.

Aloxi generated October sales of approximately $13.9 million as estimated by IMS Health (nyse: RX - news - people ), according to Prudential.

"While there are a number of confounding factors in interpreting the true Aloxi sales value, we feel that the number is weak and casts doubt on MGI's ability to meet its 2005 full-year Aloxi sales guidance of $250-$260 million," wrote analyst Jason Zhang, in a client note. "After talking with management, however, their confidence leads us to believe that MGI can indeed meet their guidance as management is not only aware of October's Aloxi sales number, but November's as well."

Aloxi is a nausea treatment for patients undergoing chemotherapy and is MGI Pharma's lead product.

The research analyst maintained an "overweight" rating and $33 price target on MGI shares. Zhang noted the stock could see near-term catalysts for experimental sedative Aquavan as well as Dacogen, a treatment for myelodysplastic syndrome (MDS), a precursor to leukemia.

forbes.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News